Physician profile
Audra Wolfe
NPI 1104301548
$3,206.87
in general payments reported to CMS, 2019-2025
29 companies · $498 in 2025
The $498 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $335 · 2022: $617 · 2023: $690 · 2024: $1,067 · 2025: $498.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,255.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,254.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $859.02 | 2021-2025 | Wegovy, Ozempic, Rybelsus |
| Abbvie INC. | $329.70 | 2021-2024 | |
| Astellas Pharma US INC | $221.34 | 2023-2024 | Veozah, Myrbetriq |
| Evofem Biosciences, INC. | $182.82 | 2022-2025 | Phexxi, Solosec, Phexx |
| Sumitomo Pharma America, INC. | $170.75 | 2024-2025 | Gemtesa, Myfembree |
| Biogen, INC. | $166.75 | 2024-2025 | Zurzuvae |
| Daiichi Sankyo INC. | $164.15 | 2021-2022 | |
| Hologic Sales and Service, LLC | $141.04 | 2022-2025 | Myosure Tissue Removal Device, Novasure, Aptima |
| Innovation Technologies INC | $131.75 | 2024 | Irrisept |
| Exeltis, USA INC. | $108.64 | 2022-2024 | Slynd |
| Axonics, INC. | $99.70 | 2023 | Axonics, Bulkamid |
| Therapeuticsmd, INC. | $87.82 | 2021-2022 | |
| Lilly USA, LLC | $76.63 | 2024 | Zepbound |
| Itamar Medical INC | $69.86 | 2023 | Watchpatone |
| Mayne Pharma Commercial LLC | $47.14 | 2025 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coloplast Corp | $39.94 | 2023 | Altis |
| Shield Therapeutics INC | $38.48 | 2024 | |
| Avion Pharmaceuticals | $36.40 | 2022-2023 | Balcoltra |
| Ibsa Pharma INC. | $34.68 | 2024-2025 | Licart, Tirosint, Flector |
| Agile Therapeutics, INC. | $31.45 | 2021 | |
| Organon LLC | $31.38 | 2024 | |
| Kyowa Kirin, INC. | $21.85 | 2024 | Poteligeo |
| Ethicon US, LLC | $21.40 | 2025 | Vistaseal |
| Coopersurgical, INC. | $19.67 | 2025 | Paragard T 380a |
| Amgen INC. | $17.01 | 2021 | |
| Millicent US INC | $15.65 | 2024 | Intrarosa |
| Currax Pharmaceuticals LLC | $14.21 | 2023 | Nexletol, Nexlizet, Contrave |
| Aspira Women'S Health INC | $14.19 | 2024 | Ova1 |
| Bausch Health US, LLC | $13.45 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Audra Wolfe listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.